A role for LRIG1 in the regulation of malignant glioma aggressiveness

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 1081-1087

  Mao, Feng ^a   Wang, Baofeng ^a   Xiao, Qungen ^a   Xi, Guifa ^a   Sun, Wei ^a   Zhang, Huaqiu ^a   Ye, Fei ^a   Wan, Feng ^a   Guo, Dongsheng ^a   Lei, Ting ^a   Chen, Xiaoping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Epidermal growth factor receptor; Glioma; Invasion; LRIG1; Migration; Proliferation

Indexed keywords

CYCLINE; GELATIN; GELATINASE A; GELATINASE B; LIGAND; LRIG1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

AGGRESSIVENESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ZYMOGRAPHY;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873636387     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1776     Document Type: Article

References (39)

1. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology and paths to treatment. Genes Dev 21: 2683-2710, 2007. (Pubitemid 350070717)
2. MacDonald TJ, Aguilera D and Kramm CM: Treatment of high-grade glioma in children and adolescents. Neurooncology 13: 1049-1058, 2011.
3. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
4. Smith JS, Tachibana I, Passe SM, et al: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001. (Pubitemid 32816199)
5. Reifenberger G and Collins VP: Pathology and molecular genetics of astrocytic gliomas. J Mol Med 82: 656-670, 2004. (Pubitemid 39468490)
6. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000. (Pubitemid 30152011)
7. Heimberger AB, Hlatky R, Suki D, et al: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11: 1462-1466, 2005. (Pubitemid 40315227)
8. Nilsson J, Vallbo C, Guo D, et al: Cloning, characterization and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161, 2001. (Pubitemid 32917959)
9. Guo D, Holmlund C, Henriksson R and Hedman H: The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84: 157-165, 2004. (Pubitemid 38760139)
10. Hedman H, Nilsson J, Guo D and Henriksson R: Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354, 2002.
11. Knuutila S, Aalto Y, Autio K, et al: DNA copy number losses in human neoplasms. Am J Pathol 155: 683-694, 1999. (Pubitemid 29426813)
12. Boelens MC, van den Berg A, Fehrmann RS, et al: Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol 218: 182-191, 2009.
13. Miller JK, Shattuck DL, Ingalla EQ, et al: Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 68: 8286-8294, 2008.
14. Sheu JJ, Lee CH, Ko JY, et al: Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 18: 2709-2716, 2009.
15. Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430, 2005. (Pubitemid 40489303)
16. Thomasson M, Hedman H, Guo D, Ljungberg B and Henriksson R: LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 89: 1285-1289, 2003. (Pubitemid 37363418)
17. Yang WM, Yan ZJ, Ye ZQ and Guo DS: LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 98: 898-902, 2006.
18. Gur G, Rubin C, Katz M, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281, 2004. (Pubitemid 39209151)
19. Laederich MB, Funes-Duran M, Yen L, et al: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056, 2004. (Pubitemid 39518360)
20. Goldoni S, Iozzo RA, Kay P, et al: A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26: 368-381, 2007. (Pubitemid 46122827)
21. Yi W, Holmlund C, Nilsson J, et al: Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 317: 504-512, 2011.
22. Stutz MA, Shattuck DL, Laederich MB, Carraway KL III and Sweeney C: LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27: 5741-5752, 2008.
23. Ye F, Gao Q, Xu T, et al: Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol 94: 183-194, 2009.
24. Nilsson J, Starefeldt A, Henriksson R and Hedman H: LRIG1 protein in human cells and tissues. Cell Tissue Res 312: 65-71, 2003. (Pubitemid 36578847)
25. Song H, Li Y, Lee J, Schwartz AL and Bu G: Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 69: 879-886, 2009.
26. Wang B, Han L, Chen R, et al: Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 8: 1018-1023, 2009.
27. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH and Yu Q: Merlin is a potent inhibitor of glioma growth. Cancer Res 68: 5733-5742, 2008.
28. Cai M, Han L, Chen R, et al: Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 278: 104-112, 2009.
29. Galis ZS, Muszynski M, Sukhova GK, et al: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75: 181-189, 1994. (Pubitemid 24187750)
30. Guo D, Nilsson J, Haapasalo H, et al: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 111: 238-246, 2006.
31. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
32. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003. (Pubitemid 36808270)
33. Stamenkovic I: Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448-464, 2003. (Pubitemid 36818245)
34. Nakada M, Okada Y and Yamashita J: The role of matrix metalloproteinases in glioma invasion. Front Biosci 8: e261-269, 2003.
35. Kodali R, Hajjou M, Berman AB, et al: Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 69: 706-715, 2006. (Pubitemid 43139733)
36. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375-1384, 2001. (Pubitemid 32936814)
37. Cox G, Jones JL and O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349-2355, 2000. (Pubitemid 30399202)
38. Huang PH, Xu AM and White FM: Oncogenic EGFR signaling networks in glioma. Sci Signal 2: re6, 2009.
39. Knobbe CB, Trampe-Kieslich A and Reifenberger G: Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31: 486-490, 2005. (Pubitemid 41337782)